STARTING A CONVERSATION ABOUT TAKHZYRO

WHAT IS TAKHZYRO?
TAKHZYRO™ (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION
TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout this guide. Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
A FIRST-OF-ITS-KIND PREVENTIVE TREATMENT
FOR HEREDITARY ANGIOEDEMA (HAE)

TAKHZYRO™ (lanadelumab-flyo) is the only subcutaneous injectable prescription medicine that is taken once every 2 weeks to prevent attacks of HAE in patients 12 years of age and older.

1 SUBCUTANEOUS SELF-INJECTION EVERY 2 WEEKS

FEWER ATTACKS OR ZERO ATTACKS IN A CLINICAL STUDY

PLASMA-FREE

In a 26-week clinical trial of 125 patients with HAE ages ≥12 years, those who took TAKHZYRO 300 mg every 2 weeks had an 87% reduction in monthly attacks, 83% fewer moderate or severe attacks, and 87% fewer attacks that needed acute treatment, compared with placebo.

In a supportive analysis, 44% of patients taking TAKHZYRO every 2 weeks had no attacks during the trial, compared with 2% in the placebo group.

The recommended starting dose is 300 mg every 2 weeks for patients beginning treatment with TAKHZYRO. If you’ve experienced zero attacks for more than 6 months, your healthcare provider might prescribe a 300 mg dose every 4 weeks. Remember to always take TAKHZYRO as prescribed by your healthcare provider.

Talk to your doctor about your current treatment plan

HAE affects everyone differently and your treatment needs may change over time. That’s why it’s important to evaluate your current treatment plan regularly to be sure your needs are being met.

Talk to your doctor about your treatment plan to see if TAKHZYRO might be right for you.

IMPORTANT SAFETY INFORMATION (cont’d)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout this guide.
Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
DISCUSSING YOUR HAE

Take a few moments to think about your current treatment(s). Fill out this profile and take it with you to your next doctor's appointment. Your answers to the questions below may help you more easily discuss details about your hereditary angioedema (HAE).

**Patient profile**
When were you diagnosed with HAE?

**Current HAE treatment**

<table>
<thead>
<tr>
<th>What is your current treatment plan?</th>
<th>What are the important considerations about treatment plans that you would like to discuss with your doctor?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventive</td>
<td>Attack frequency</td>
</tr>
<tr>
<td>Acute</td>
<td>Attack severity</td>
</tr>
<tr>
<td>Both preventive and acute</td>
<td>Treatment type (eg, acute/preventive)</td>
</tr>
<tr>
<td>None</td>
<td>Treatment efficacy and safety</td>
</tr>
</tbody>
</table>

How long have you been taking your current treatment(s)?

How often are you taking your current treatment(s)?

Are you interested in discussing new treatment options?

Please explain your answer below.

**IMPORTANT SAFETY INFORMATION (cont'd)**

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
DISCUSSING YOUR HAE
(continued)

**Frequency, duration, and severity of attacks**

How many HAE attacks have you experienced in the last 6 months?
Please include all attacks you have experienced, even those you may consider minor.

What areas of your body are affected by an HAE attack?
- Face
- Throat
- Stomach
- Hands
- Genitals
- Feet
- Other

Rate the average severity of your HAE attacks:
- Mild
- Moderate
- Severe

Have you been hospitalized in the past year due to an HAE attack?
- Yes
- No

---

**IMPORTANT SAFETY INFORMATION**

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout this guide. Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
QUESTIONS TO DISCUSS WITH YOUR DOCTOR

During your next appointment, you can make the most of the time you have with your doctor by having a discussion about your condition and your treatment options. Here are some questions you may find helpful to ask. You can use the space below to write down answers to help you remember what you discussed.

- Can we review my treatment plan? What other options are available to me to help manage my HAE?

- Should we establish goals when it comes to managing my HAE (eg, attack frequency, attack severity, other)?

- What factors should I consider to stay on track with my HAE goals?

IMPORTANT SAFETY INFORMATION (cont’d)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout this guide. Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
QUESTIONS TO DISCUSS WITH YOUR DOCTOR (continued)

- Is TAKHZYRO™ (lanadelumab-flyo) appropriate for me?

- How is TAKHZYRO different from my current treatment(s)?

- How do I find out if my insurance covers TAKHZYRO?

IMPORTANT SAFETY INFORMATION (cont’d)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
FREQUENTLY ASKED QUESTIONS ABOUT TAKHZYRO

With TAKHZYRO™ (lanadelumab-flyo), it's possible to help prevent HAE attacks, with 1 subcutaneous self-injection every 2 weeks.

Want to learn more about TAKHZYRO? We anticipated some questions you may have and have provided answers that you may find helpful.

**Q: What patients were included in the clinical study with TAKHZYRO?**

**A:** TAKHZYRO was studied in the largest HAE clinical trial across a range of patients:
- 125 patients
- Age range from 12 to 73 years
- 70% of patients were female
- With or without previous experience with preventive treatment
- With or without a history of laryngeal (throat) attacks
- High or low number of HAE attacks at baseline
  - 52% of patients had ≥3 attacks per month

**Q: How often do most patients take TAKHZYRO?**

**A:** The recommended starting dose is 300 mg every 2 weeks for patients beginning treatment with TAKHZYRO. If you’ve experienced zero attacks for more than 6 months, your healthcare provider might prescribe a 300 mg dose every 4 weeks.

**Q: How is TAKHZYRO administered?**

**A:** TAKHZYRO is a subcutaneous injection you give yourself after being trained by a healthcare provider. You have 3 injection site choices: stomach (abdomen), either thigh, or either arm.

**Q: How long does it take to administer TAKHZYRO?**

**A:** It took ≤1 minute to self-inject TAKHZYRO for the majority of patients. TAKHZYRO comes in a ready-to-use, single-dose vial that does not require reconstitution.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

Please see additional Important Safety Information throughout this guide.
Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
Q: How well does TAKHZYRO work?
A: In a 26-week clinical trial of 125 patients with HAE ages ≥12 years, those who took TAKHZYRO™ (lanadelumab-flyo) 300 mg every 2 weeks compared with placebo had:

- An 87% reduction in monthly attacks
- 83% fewer moderate or severe attacks
- 87% fewer attacks that needed acute treatment

Those taking TAKHZYRO 300 mg every 4 weeks compared with placebo had:

- A 73% reduction in monthly attacks
- 73% fewer moderate or severe attacks
- 74% fewer attacks that needed acute treatment

Over the entire 6.5-month study, 44% of patients taking TAKHZYRO 300 mg every 2 weeks had no attacks, compared with 2% of patients taking placebo.

- In a supportive analysis of the last 4 months of the clinical study (after 6 doses), nearly 8 out of 10 (77%) patients had zero attacks with TAKHZYRO 300 mg every 2 weeks, compared with 3% of patients taking placebo.

- Although not the main focus of the study, these results support its primary findings. The study was not designed in advance to measure the percentage of attack-free patients during the last 4 months of the study.

Q: What are the most common side effects with TAKHZYRO?
A: Injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache were the most common side effects seen with TAKHZYRO. These are not all the possible side effects of TAKHZYRO.

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have symptoms of an allergic reaction.

Q: What support services are available for TAKHZYRO?
A: Shire provides ongoing support to help eligible patients every step of the way through personalized product support services:

- OnePath®—a free product support program: A dedicated Patient Support Manager (PSM) can connect you and your caregivers to programs and resources to meet your individual access needs

IMPORTANT SAFETY INFORMATION (cont’d)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout this guide.
Please see complete Patient Information after page 9 and full Prescribing Information located at www.TAKHZYRO.com.
WHAT IS TAKHZYRO?
TAKHZYRO™ (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.
It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION
TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see complete Patient Information on the next page and full Prescribing Information located at www.TAKHZYRO.com.
Read this Patient Information before you start using TAKHZYRO and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is TAKHZYRO?
TAKHZYRO is a prescription medicine used to prevent attacks of Hereditary Angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Before you use TAKHZYRO, tell your healthcare provider about all of your medical conditions, including if you:
• are pregnant or planning to become pregnant. It is not known if TAKHZYRO can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if TAKHZYRO passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby while using TAKHZYRO.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.

How should I use TAKHZYRO?
• See the detailed “Instructions for Use” that comes with this patient information leaflet about the right way to prepare and inject TAKHZYRO.
• Use TAKHZYRO exactly as your healthcare provider tells you to use it.
• TAKHZYRO is given as an injection under your skin (subcutaneous) by you or a caregiver.
• Your healthcare provider should show you or your caregiver how to prepare and inject your dose of TAKHZYRO before you inject yourself for the first time.
• Do not try to inject TAKHZYRO unless you have been trained by your healthcare provider.

What are the possible side effects of TAKHZYRO?
TAKHZYRO may cause serious side effects, including allergic reactions. Allergic reactions may happen with TAKHZYRO. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:
• wheezing
• difficulty breathing
• chest tightness
• fast heartbeat
• faintness
• rash
• hives

The most common side effects of TAKHZYRO are:
• injection site reactions (pain, redness, and bruising)
• upper respiratory infections
• headache

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

General information about the safe and effective use of TAKHZYRO
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAKHZYRO for a condition for which it is not prescribed. Do not give TAKHZYRO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAKHZYRO that is written for health professionals.

What are the ingredients in TAKHZYRO?
Active ingredient: lanadelumab
Inactive ingredients: citric acid monohydrate, L-histidine, sodium chloride, sodium phosphate dibasic dihydrate and water for injection.

Manufactured by: Dyax Corp, 300 Shire Way, Lexington, MA 02421
U.S. License No. 1789
TAKHZYRO™ is a trademark or registered trademark of Dyax Corp., a wholly-owned, indirect subsidiary of Shire plc. SHIRE and the Shire Logo are trademarks or registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
©2018 Shire. All rights reserved.
For more information, visit www.TAKHZYRO.com or call 1-800-828-2088.

This Patient Information has been approved by the U.S. Food and Drug Administration
S40780 Issued: 8/2018